Theriva Biologics Secures $4M Incentive Warrant Deal, Plans to Boost Cash Flow

Theriva Biologics announced a warrant incentive deal worth a gross $4 million. The deal involves the immediate exercise of warrants to buy up to 7,360,460 shares at a reduced exercise price of $0.54 per share. The company plans to use the net proceeds for general corporate purposes. A.G.P./Alliance Global Partners acted as the exclusive financial advisor for the transaction. The new warrants were offered in a private placement exempt from US securities laws.

Theriva Biologics (NYSE American: TOVX) has announced a warrant inducement agreement, generating approximately $4 million in gross proceeds. The deal involves the immediate exercise of up to 7,360,460 existing warrants at a reduced price of $0.54 per share. The net proceeds will be used for working capital and general corporate purposes. The transaction was advised by A.G.P./Alliance Global Partners.

In return for exercising the existing warrants, investors will receive new unregistered warrants to purchase up to 14,720,920 shares at the same $0.54 exercise price. These new warrants will be exercisable after shareholder approval and expire five years after the approval date. The closing of the transaction is expected on or about October 17, 2025.

The deal provides immediate liquidity for the company while deferring substantial dilution until the new warrants become exercisable. The success of the transaction hinges on shareholder approval and the filing and effectiveness of the registration statement with the SEC, which will determine when the new warrants can be converted into stock and the ultimate cash inflow from their exercise.

This transaction allows Theriva Biologics to secure near-term working capital while deferring future dilution. The company plans to use the proceeds for general corporate purposes, with the new warrants remaining unregistered until a registration statement is filed.

Key factors to watch include the closing date of the transaction, the filing and effectiveness of the registration statement, and any shareholder vote outcomes over the coming weeks. The deal converts existing warrants into immediate cash at a reduced price and grants replacement warrants that total twice the number of shares underlying the exercised warrants. The company will use the net proceeds for working capital and general corporate purposes.